nivolumab   Click here for help

GtoPdb Ligand ID: 7335

Synonyms: BMS-936558 | MDX-1106 | ONO-4538 | Opdivo®
Approved drug Immunopharmacology Ligand
nivolumab is an approved drug (FDA (2014), EMA (2015))
Compound class: Antibody
Comment: Nivolumab is an IgG4 kappa immunoglobulin that is selective for PD-1, an immune-checkpoint receptor expressed on activated T-cells, monocytes, B-cells, natural killer (NK) T-cells, and dendritic cells [12]. This monoclonal is produced in Chinese hamster ovary cells by recombinant DNA technology. Nivolumab is an immuno-oncology drug.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Sequence analysis of the light and heavy chain variable region peptides of nivolumab shows exact matches with claimed peptide sequences of monoclonal 5C4 contained in patent WO2006121168 [10].
Click here for help
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
programmed cell death 1 (CD279) Primary target of this compound Hs Antibody Binding 9.1 pKd - 5,9-10
⤷ pKd 9.1 (Kd 7.3x10-10 M) [5,9-10]
programmed cell death 1 (CD279) Primary target of this compound Hs Antibody Binding 10.3 pEC50 - 20
⤷ pEC50 10.3 (EC50 5.3x10-11 M) [20]
programmed cell death 1 (CD279) Monkey Antibody Binding 9.4 pEC50 - 20
⤷ pEC50 9.4 (EC50 4x10-10 M) [20]